Short Interest in Tema Oncology ETF (NASDAQ:CANC) Rises By 453.8%

Tema Oncology ETF (NASDAQ:CANC) saw a significant increase in short interest during the month of February. As of February 28th, there was short interest totalling 7,200 shares, an increase of 453.8% from the February 13th total of 1,300 shares. Approximately 0.3% of the shares of the company are short sold. Based on an average daily volume of 19,700 shares, the days-to-cover ratio is currently 0.4 days.

Tema Oncology ETF Stock Performance

NASDAQ:CANC opened at $25.16 on Thursday. Tema Oncology ETF has a one year low of $23.97 and a one year high of $30.11. The firm has a market cap of $64.16 million, a price-to-earnings ratio of 26.86 and a beta of 1.11. The firm’s fifty day moving average is $25.20 and its two-hundred day moving average is $26.77.

Institutional Investors Weigh In On Tema Oncology ETF

An institutional investor recently raised its position in Tema Oncology ETF stock. Thrivent Financial for Lutherans lifted its position in shares of Tema Oncology ETF (NASDAQ:CANC) by 25.1% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 399,509 shares of the company’s stock after acquiring an additional 80,133 shares during the quarter. Thrivent Financial for Lutherans owned 22.96% of Tema Oncology ETF worth $11,351,000 as of its most recent SEC filing.

Tema Oncology ETF Company Profile

The Tema Oncology ETF (CANC) is an exchange-traded fund that mostly invests in health care equity. The fund is actively managed, investing in stocks of companies focused on cancer treatment and management from issuers all around the world. The fund uses a bottom-up approach to select pioneering companies at perceived attractive valuations CANC was launched on Aug 15, 2023 and is issued by Tema.